Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability and effect on blood glucose control of BMS-903452 compared to placebo in healthy subjects \& relative bioavailability of the crystalline and amorphous forms of BMS-903452 \[Panels 4,6,11 \& 12(Part A)\] ; and subjects with type 2 Diabetes Mellitus (Part B). The study will also determine the amount of BMS-903452 in the blood.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Comprehensive Phase One
Miramar, Florida, United States
Ppd Development, Lp
Austin, Texas, United States
Start Date
November 1, 2010
Primary Completion Date
January 1, 2012
Completion Date
January 1, 2012
Last Updated
March 15, 2012
104
ACTUAL participants
BMS-903452
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
Placebo
DRUG
Placebo
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
Placebo
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
BMS-903452
DRUG
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07296484